Metabolic biomarkers for predicting cardiovascular disease

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 37-45

  Montgomery, Jana E ^a,b   Brown, Jeremiah R ^a,c  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

Author keywords

Cardiac biomarkers; Cardiovascular disease

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM; CHOLESTEROL ESTER TRANSFER PROTEIN; D DIMER; FERRITIN; FIBRINOGEN; HAPTOGLOBIN; HOMOCYSTEINE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; URIC ACID; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

AREA UNDER THE CURVE; ARTERIAL WALL THICKNESS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CORONARY ARTERY CALCIUM SCORE; EVENT FREE SURVIVAL; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; LEUKOCYTE COUNT; MEDICAL RESEARCH; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTION; PROBABILITY; PROGNOSIS; PULSE WAVE; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK ASSESSMENT; UNITED STATES;

CARDIAC BIOMARKERS; CARDIOVASCULAR DISEASE;

ANIMALS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HEALTH CARE COSTS; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 84873821419     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S30378     Document Type: Review

References (73)

1. Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood). 2007;26(1):38-48.
2. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353(9147):89-92.
3. National Heart L, and Blood Institute. FY 2011 Fact Book. 2011. Available from: http://www.nhlbi.nih.gov/about/factbook/FactBook2011.pdf. Accessed August 24, 2012.
4. Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119(17):2408-2416.
5. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113(19):2335-2362.
6. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95.
7. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease-six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33-50.
8. Stampfer MJ, Ridker PM, Dzau VJ. Risk factor criteria. Circulation. 2004;109(25 Suppl 1):IV3-IV5.
9. Wilkins JT, Lloyd-Jones DM. Biomarkers for coronary heart disease clinical risk prediction: a critical appraisal. Counterpoint. Prev Cardiol. 2010;13(4):160-165.
10. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157-172; discussion 207212.
11. Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol. 2009;38(1):217-231.
12. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122(25):2748-2764.
13. Wilson PW. Challenges to improve coronary heart disease risk assessment. JAMA. 2009;302(21):2369-2370.
14. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355(25):2631-2639.
15. Kavousi M, Elias-Smale S, Rutten JH, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med. 2012;156(6):438-444.
16. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006;166(13):1368-1373.
17. Reichlin T, Schindler C, Drexler B, et al. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Arch Intern Med. 2012;172(16):1211-1218.
18. Nadir MA, Rekhraj S, Wei L, et al. Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. J Am Coll Cardiol. 2012;60(11):960-968.
19. Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290(7):891-897.
20. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290(7): 898-904.
21. Ptolemy AS, Rifai N. What is a biomarker? Research investments and lack of clinical integration necessitate a review of biomarker terminology and validation schema. Scand J Clin Lab Invest Suppl. 2010;242:6-14.
22. Palazzuoli A, Iovine F, Gallotta M, Nuti R. Emerging cardiac markers in coronary disease: role of brain natriuretic peptide and other biomarkers. Minerva Cardioangiol. 2007;55(4):491-496.
23. Rana JS, Gransar H, Wong ND, et al. Comparative value of coronary artery calcium and multiple blood biomarkers for prognostication of cardiovascular events. Am J Cardiol. 2012;109(10):1449-1453.
24. Dong B, Ji W, Zhang Y. Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome. Intern Med. 2011;50(10):1093-1097.
25. Wang JH, Lee CJ, Lee CC, Chen YC, Lee RP, Hsu BG. Fasting adiponectin is inversely correlated with metabolic syndrome in patients with coronary artery disease. Intern Med. 2010;49(8):739-747.
26. Saely CH, Vonbank A, Rein P, et al. Alanine aminotransferase and gamma-glutamyl transferase are associated with the metabolic syndrome but not with angiographically determined coronary atherosclerosis. Clin Chim Acta. 2008;397(1-2):82-86.
27. Yano Y, Toshinai K, Inokuchi T, et al. Plasma des-acyl ghrelin, but not plasma HMW adiponectin, is a useful cardiometabolic marker for predicting atherosclerosis in elderly hypertensive patients. Atherosclerosis. 2009;204(2):590-594.
28. Tzotzas T, Desrumaux C, Lagrost L. Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor. Obesity Rev. 2009;10(4):403-411.
29. Gopaul KP, Crook MA. Sialic acid: a novel marker of cardiovascular disease? Clin Biochem. 2006;39(7):667-681.
30. Marian AJ, Nambi V. Biomarkers of cardiac disease. Exp Rev Mol Diagn. 2004;4(6):805-820.
31. Reynolds RM, Ilyas B, Price JF, et al. Circulating plasma cortisol concentrations are not associated with coronary artery disease or peripheral vascular disease. QJM. 2009;102(7):469-475.
32. Koenig W. Update on integrated biomarkers for assessment of longterm risk of cardiovascular complications in initially healthy subjects and patients with manifest atherosclerosis. Ann Med. 2009;41(5): 332-343.
33. Shlipak MG, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study. Am J Med. 2008;121(1):50-57.
34. Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of Pneumococcus. J Exper Med. 1930;52(4):561-571.
35. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 2004;29(8):439-493.
36. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001;103(9):1194-1197.
37. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102(18):2165-2168.
38. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol. 2006;48(1):1-11.
39. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA. 2002;288(8):980-987.
40. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973-979.
41. Cannon CP, Steinberg BA. Evidence-Based Cardiology. Philadelphia, PA: Wolters Kluwer; 2011.
42. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557-1565.
43. Dupuis J, Tardif JC, Rouleau JL, et al. Cannon CP. Intensity of lipid lowering with statin and brachial artery vascular endothelium reactivity after acute coronary syndromes. Am J Cardiol. 2005 Nov 1; 96(9): 1207-1213.
44. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004; 291(9):1071-1080.
45. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959-1965.
46. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
47. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349(9050): 462-466.
48. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol. 2006;47(Suppl 8):C19-C31.
49. Milazzo D, Biasucci LM, Luciani N, et al. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. Am J Cardiol. 1999;84(4):459-461, A459.
50. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98(9):839-844.
51. Mueller C, Buettner HJ, Hodgson JM, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation. 2002;105(12):1412-1415.
52. Wensley F, Gao P, Burgess S, et al. Association between C-reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548.
53. Elliott P, Chambers JC, Zhang W, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009;302(1):37-48.
54. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145(1):21-29.
55. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the US Preventive Services Task Force. Ann Intern Med. 2009;151(7):483-495.
56. Konstantino Y, Wolk R, Terra SG, Nguyen TT, Fryburg DA. Non-traditional biomarkers of atherosclerosis in stable and unstable coronary artery disease, do they differ? Acute Cardiac Care. 2007;9(4):197-206.
57. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362-1370.
58. Albert MA. Biomarkers and heart disease. J Clin Sleep Med. 2011;7(Suppl 5):S9-S11.
59. Disease CoQoBaSEiC, Medicine Io. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. Washington, DC: National Academies Press; 2010.
60. Kim HC. Clinical utility of novel biomarkers in the prediction of coronary heart disease. Korean Circ J. 2012;42(4):223-228.
61. National Heart Lung, and Blood Institute. FY 2011 Fact Book. 2011. Available from: http://www.nhlbi.nih.gov/about/factbook/FactBook2011.pdf. Accessed August 24, 2012.
62. Garg A. What is the role of alternative biomarkers for coronary heart disease? Clinical endocrinology. Sep 2011;75(3):289-293.
63. Herder C, Karakas M, Koenig W. Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. Clin Pharmacol Ther. 2011;90(1):52-66.
64. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, StehmanBreen C, Bleyer A, Newman A, Siscovick D, Psaty B. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005; 293(14):1737-1745.
65. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355(25):2631-2639.
66. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006;166(13):1368-1373.
67. Zethelius B, Berglund L, Sundström J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358(20):2107-2116.
68. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009;302(1):49-57.
69. Blankenberg S, Zeller T, Saarela O, et al. MORGAM Project. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation. 2010; 121(22):2388-2397.
70. Sattar N, Murray HM, Welsh P, et al. Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group. Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? PLoS Med. 2009;23;6(6):e1000099.
71. de Ruijter W, Westendorp RG, Assendelft WJ, et al. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ. 2009;338:a3083.73.
72. Schnabel RB, Schulz A, Messow CM, et al. Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J. 2010;31(24):3024-3031.
73. Herder C, Baumert J, Zierer A, et al. Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study. PLoS One. 2011;6(6):e19852.